ResMed Inc. (RMD.AX)
| Previous close | 33.10 |
| Open | 32.74 |
| Bid | 32.70 x 51100 |
| Ask | 32.96 x 25600 |
| Day's range | 32.74 - 33.07 |
| 52-week range | 21.14 - 34.27 |
| Volume | |
| Avg. volume | 2,353,415 |
| Market cap | 48.46B |
| Beta (5Y monthly) | 0.64 |
| PE ratio (TTM) | 33.45 |
| EPS (TTM) | 0.98 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | 0.29 (0.88%) |
| Ex-dividend date | 08 May 2024 |
| 1y target est | 35.00 |
GlobeNewswireATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- When: May 17–22, 2024Where: San Diego Convention Center (SDCC) | 111 Harbor Dr. San Diego, CA 92101 Marriott Marquis San Diego Marina | 333 West Harbor Dr. San Diego, CA 92101 Research: 26 ResMed-supported abstracts will be presented at ATS. Full list below. Highlights: Treatment of Sleep-Disordered Breathing with Adaptive Servo-Ventilation (READ-ASV) in Opioid Users – a European Registry Sunday May 19, 2024, 9:15 a.m. - 11:15 a.m., SDCC 32A-BPresented
ZacksWhat Makes ResMed (RMD) a New Strong Buy Stock
ResMed (RMD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ZacksPrestige Consumer (PBH) Q4 Earnings Miss, Operating Margin Falls
Prestige Consumer's (PBH) Q4 business suffers from supply chain pressure that impacts its ability to fulfill retailer orders.
